Full Text View
Tabular View
No Study Results Posted
Related Studies
Assessment of Symptom-Related Cytokines in Lung and Gastrointestinal (GI) Cancer Patients
This study is ongoing, but not recruiting participants.
First Received: July 16, 2007   Last Updated: February 20, 2009   History of Changes
Sponsors and Collaborators: M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Information provided by: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT00502502
  Purpose

Primary Objectives:

  • To determine the feasibility of a study that would describe changes of certain circulating inflammatory cytokines (interleukin-1, 6, 8, 10, 12, and tumor necrosis factor-alpha [TNF] and symptoms related to chemoradiation therapy (pre-therapy, during therapy and up to 3 months post-therapy) among patients with lung, esophageal, gastric, colorectal and anal cancer.
  • To determine the feasibility of studying neurocognitive function in patients with non-small cell lung cancer (NSCLC) at presentation and during chemoradiation therapy to determine the prevalence, severity, and pattern of cognitive symptoms.

Condition Intervention
Anal Cancer
Colorectal Cancer
Esophageal Cancer
Gastric Cancer
Lung Cancer
Behavioral: Questionnaire

Study Type: Observational
Study Design: Case-Only, Prospective
Official Title: Feasibility Study of the Assessment of Symptom-Related Cytokines in Lung and GI Cancer Patients Undergoing Chemoradiation Therapy

Resource links provided by NLM:


Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • To learn about chemoradiation therapy symptoms in patients with lung, esophageal, gastric, colorectal, and anal cancer. [ Time Frame: 7 Years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Biospecimen Description:

Blood samples will be collected to study the levels of cytokines in your blood.


Estimated Enrollment: 225
Study Start Date: November 2002
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1
Questionnaire
Behavioral: Questionnaire
Questionnaires lasting about 30 minutes.

Detailed Description:

One of the ways to learn about the symptoms of chemoradiation therapy is by looking at how certain proteins called cytokines (found in the blood) change during therapy. Another way is to look at how thinking and memory may be changed because of treatment.

Before therapy starts, you will be asked to complete several questionnaires during a visit to the Radiation Oncology clinic at M. D. Anderson. These questionnaires measure physical and emotional symptoms. These questionnaires should take about 30 minutes to finish. Lung cancer patients will also complete some cognitive (mental) questionnaires. During this visit, the research nurse will teach you how to use the telephone system for measuring symptoms. You will tell the system the most convenient times for the telephone calls. The date of the call will be at the same or close to the date of your weekly clinic visit.

Before you begin your chemoradiation treatments, you will have a sample of blood drawn (around 2½ tablespoons).

The sample of blood will be used to measure levels of cytokines in your blood pre treatment.

You will have about 2½ tablespoons of blood drawn again when you start chemoradiation, and then once a week while you are receiving treatment. These cytokines may be related to symptoms experienced while having treatment for cancer. These blood tests are being done to study the levels of cytokines in your blood during, and after treatment for cancer.

Symptoms will be monitored weekly using an interactive voice response telephone system. During chemoradiation, the automated telephone system will call you once a week to ask you to rate your symptoms and how much the symptoms interfere in your daily life. The information collected by these calls is only being used for this research study.

At the end of the chemoradiation, lung cancer patients will again be given questionnaires to measure cognitive symptoms.

For lung cancer patients who are post-chemotherapy, your symptoms will be monitored weekly for 3 months after therapy using the interactive voice response telephone system. For esophageal, gastric, colorectal, and anal patients who are post-therapy, your symptoms will be monitored weekly for 6 weeks after therapy using the interactive voice response telephone system. About 30 days after chemoradiation, you will have 2½ tablespoons of blood drawn at your regularly scheduled clinic visit. If you are not scheduled for a 3 month clinic visit, we will contact your local physician for blood lab results.

This is an investigational study. About 225 evaluable patients will take part in this study. All will be enrolled at M. D. Anderson.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Study participants with lung, esophageal, gastric, colorectal or anal cancer.

Criteria

Inclusion Criteria:

  1. Patients scheduled for chemoradiation therapy at MDACC.
  2. Adults > 18 years of age.
  3. Diagnosis of lung, esophageal, gastric, colorectal, or anal cancer.
  4. English-speaking.
  5. Lives in the United States.
  6. Adequate vision and hearing to use the IVR system.
  7. Provides written informed consent.

Exclusion Criteria:

  1. Patients with a current diagnosis of psychosis or dementia.
  2. Patients who are unable to complete the assessment measures or refuse to participate.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00502502

Locations
United States, Texas
U.T. M.D. Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Investigators
Principal Investigator: Xin Shelley Wang, MD M.D. Anderson Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: U.T. M.D. Anderson Cancer Center ( Xin Shelley Wang, MD/Associate Professor )
Study ID Numbers: ANS02-495
Study First Received: July 16, 2007
Last Updated: February 20, 2009
ClinicalTrials.gov Identifier: NCT00502502     History of Changes
Health Authority: United States: Institutional Review Board

Keywords provided by M.D. Anderson Cancer Center:
Anal Cancer
Colorectal Cancer
Esophageal Cancer
Gastric Cancer
Lung Cancer
Questionnaire
Survey
Chemoradiation Therapy
Symptoms
Cytokines

Study placed in the following topic categories:
Thoracic Neoplasms
Gastrointestinal Diseases
Rectal Neoplasms
Esophageal Neoplasms
Colonic Diseases
Anal Cancer
Rectal Diseases
Stomach Diseases
Respiratory Tract Diseases
Lung Neoplasms
Stomach Neoplasms
Digestive System Neoplasms
Rectal Neoplasm
Esophageal Cancer
Intestinal Diseases
Intestinal Neoplasms
Digestive System Diseases
Rectal Cancer
Esophageal Disorder
Head and Neck Neoplasms
Lung Diseases
Gastrointestinal Neoplasms
Esophageal Diseases
Stomach Cancer
Anus Neoplasms
Colorectal Neoplasms

Additional relevant MeSH terms:
Thoracic Neoplasms
Respiratory Tract Neoplasms
Digestive System Neoplasms
Gastrointestinal Diseases
Rectal Neoplasms
Esophageal Neoplasms
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Intestinal Neoplasms
Neoplasms
Stomach Diseases
Neoplasms by Site
Digestive System Diseases
Respiratory Tract Diseases
Lung Neoplasms
Lung Diseases
Head and Neck Neoplasms
Stomach Neoplasms
Gastrointestinal Neoplasms
Esophageal Diseases
Anus Diseases
Anus Neoplasms
Colorectal Neoplasms

ClinicalTrials.gov processed this record on September 11, 2009